ScreenerHero

KURAKura Oncology, Inc.

NAS · US · Healthcare · Biotechnology · kuraoncology.com
11.89USD-5.11%Mkt Cap: 1.06B $P/E: —

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral sma…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.06B $
Enterprise Value547.16M $
Revenue (TTM)77.22M $
Gross Profit67.42M $
Net Income (TTM)-278.67M $
Revenue/Share0.8750 USD
Last Price11.89 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.09
PEG—
EV/EBITDA-1.73
EV/Revenue7.09
P/S13.49
P/B21.53
EPS (TTM)-3.15
EPS (Forward)-2.30
52W Range
6.95083% of range12.90
52W High12.90 USD
52W Low6.950 USD
Profitability
Gross Margin99.92%
Oper. Margin-349.77%
EBITDA Margin0.00%
Profit Margin-412.95%
ROE-160.03%
ROA-37.74%
Growth
Revenue Growth36.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.06M $
CapEx (TTM)6.64M $
FCF Margin-214.80%
FCF Yield-15.68%
Net Debt-494.57M $
Net Debt/EBITDA1.56
Balance Sheet
Debt/Equity0.12
Current Ratio4.73
Quick Ratio4.50
Book Value/Sh0.5440 USD
Cash/Share5.834 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)32.00 USD
Upside (mean)+169.1%
Target Range15.00 USD – 76.00 USD
$15.00+169.1% to mean$76.00
# Analysts12
Ownership
Shares Out.88.96M
Float70.60M
Insiders1.43%
Institutions99.62%
Short Interest
Short Ratio9.1d
Short % Float15.22%
Short % Out.14.83%
Shares Short13.16M
Short (prev mo.)15.09M
Technical
SMA 5010.41 (+14.3%)
SMA 2009.669 (+23.0%)
Beta0.38
S&P 52W Chg18.16%
Avg Vol (30d)1.42M
Avg Vol (10d)2.32M
Technical Indicators
RSI (14)65.3
MACD0.3273
MACD Signal0.0132
MACD Hist.+0.3142
BB Upper11.98 USD
BB Middle10.03 USD
BB Lower8.079 USD
BB Width38.92%
ATR (14)0.6619 USD
Vol Ratio (20d)1.28x